fda glp-1 compounding warning letters october 2025 issues first cGMP letter citing AI misuse in pharmaceutical manufacturing FDA Issues Five Warning Letters

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, tirzepatide) slow gastrointestinal transit, causing constipation in up to 1 in 10 patients

It also supports improved endurance and performance

The EXSCEL trial (Bethel et al., 2020) and LEADER trial (Marso et al., 2016) investigated the effect of exenatide and liraglutide, respectively, on microvascular and cardiovascular outcomes in patients with type 2 diabetes

Malaguarnera M, et al

Even on GLP-1s, which help regulate insulin and blood sugar levels, your body will eventually adapt to the medication and your new, lower body weight

I'm a great place to add more information about your product such as sizing, material, care and cleaning instructions